Pasritamig Shows Strong Phase 1b Results in mCRPC
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
mCRPC
Advertisement
J&J Pasritamig Combo Shows Strong mCRPC Activity
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
SECuRE Trial: Undetectable Disease With 67Cu-SAR-bisPSMA
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
C-Ray Therapeutics Unveils Promising 225Ac-PSMA-CY313 Clinical Data at EANM 2025
BARCELONA, Spain, Oct. 8, 2025 — During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM...
Advertisement
